Thyroid Gland Disorder Treatment Market

Thyroid Gland Disorder Treatment Market Size and Share:

The global thyroid gland disorder treatment market size was valued at USD 2.6 Billion in 2024. Looking forward, the market is expected to reach USD 3.3 Billion by 2033, exhibiting a CAGR of 2.99% during 2025-2033. North America currently dominates the market, holding a significant market share of 40.7% in 2024. The rising prevalence of hyperthyroidism and hypothyroidism, increasing utilization of effective combination drug therapies, and the wide availability of undiagnosed patients of thyroid gland disorder represent some of the key factors driving the thyroid gland disorder treatment market share.

The market is primarily driven by the increasing prevalence of thyroid-related conditions, including hyperthyroidism and hypothyroidism, affecting millions globally. Rising public awareness about early diagnosis and effective treatment options is encouraging timely medical intervention, while government and non-government initiatives promoting disease awareness further support market growth. The adoption of combination drug therapies and patient-friendly formulations, such as oral tablets, enhances treatment efficacy and compliance. Lifestyle-related factors, including iodine deficiency, alcohol consumption, and tobacco use, are increasing the risk of thyroid disorders, thereby fueling demand for treatments. Additionally, advancements in healthcare infrastructure, investments in research and development, and the availability of innovative therapeutic options significantly contribute to the expansion of the thyroid disorder treatment market worldwide.

The thyroid gland disorder treatment market growth in the United States is driven by the rising prevalence of thyroid-related conditions, including hypothyroidism and hyperthyroidism, which affect millions of individuals nationwide. Increasing awareness about early diagnosis and the benefit of effective treatment is encouraging timely intervention, supported by government-led screening programs and disease awareness initiatives. The growing adoption of combination drug therapies and easy-to-administer oral medications enhances patient compliance and treatment outcomes. Lifestyle-related factors, such as iodine deficiency, tobacco use, and alcohol consumption, further elevate the risk of thyroid disorders, increasing demand for therapeutic solutions. Additionally, strong healthcare infrastructure, robust insurance coverage, and ongoing research and development of innovative drugs are fueling market growth. For instance, in April 2024, Verana Health, a digital healthcare company focused on transforming patient care and clinical research through real-world data (RWD), introduced its Qdata Thyroid Eye Disease (TED) module.

Thyroid Gland Disorder Treatment Market Trends:

Rising Prevalence of Thyroid Disorders and Healthcare Support

The growing incidence of both hyperthyroidism and hypothyroidism is a primary driver of market expansion. Thyroid diseases already affect an estimated 200 million people worldwide, while around 40% of the global population, about 2.8 billion individuals, remains at risk. This widespread vulnerability is prompting stronger healthcare responses and larger investments in diagnosis and treatment. For instance, according to the India Brand Equity Foundation, the Indian government allocated Rs. 99,858 crore (USD 11.50 billion) in the Union Budget 2025–26 to upgrade and maintain the healthcare system. Such substantial funding ensures better screening, improved medical infrastructure, and access to therapies, thereby supporting sustained growth in the thyroid disorder treatment market.

Expanding Awareness and Advanced Treatment Options

Increasing public awareness of the benefits of early thyroid disorder treatment is significantly influencing market demand. Government and non-government bodies are implementing disease awareness campaigns that highlight symptoms, risks, and treatment choices, creating lucrative opportunities for industry stakeholders. At the same time, the adoption of effective combination drug therapies is gaining traction for managing thyroid conditions more efficiently. According to the thyroid gland disorder treatment market trends, these multi-drug regimens improve outcomes and patient compliance, fueling market growth. Moreover, the asymptomatic nature of many thyroid disorders results in a large pool of undiagnosed patients. This untapped segment strengthens the need for proactive testing and medication, encouraging continuous development of innovative therapeutic solutions.

Lifestyle Factors and Increasing Demand for Convenient Medication

Lifestyle-related issues such as iodine deficiency, rising alcohol consumption, and widespread tobacco use are amplifying thyroid health risks. According to the WHO, the tobacco epidemic remains one of the largest public health challenges, causing over 7 million deaths annually and contributing to long-term illnesses. These factors heighten the prevalence of thyroid disorders, accelerating treatment demand. Furthermore, there is a growing preference for easily administered tablets and pills, which enable patients to follow consistent daily regimens. This convenience, combined with the global rise in iodine deficiency, reinforces the need for regular pharmaceutical treatments, thereby driving the expansion of the thyroid disorder treatment market worldwide.

Thyroid Gland Disorder Treatment Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global thyroid gland disorder treatment market, along with forecasts at the global, regional, and country levels from 2025-2033. The market has been categorized based on drug type, diseases type, route of administration, and distribution channel.

Analysis by Drug Type:

• Levothyroxine
• Liothyronine
• Propylthiouracil
• Imidazole-Based Compound
• Others

Levothyroxine leads the market with 70% of market share in 2024, owing to its widespread use as the standard therapy for hypothyroidism. It effectively restores normal thyroid hormone levels, alleviating symptoms such as fatigue, weight gain, and cognitive impairment. Its long-standing clinical efficacy, safety profile, and consistent absorption make it the preferred choice among endocrinologists. The availability of multiple dosage strengths allows for personalized treatment, ensuring optimal patient outcomes. Both branded and generic formulations are widely accessible, further boosting their adoption across developed and emerging markets. Continuous research into improved bioavailability and extended-release versions, along with strong physician confidence, reinforces levothyroxine’s leading share in global thyroid disorder management.

 Analysis by Diseases Type:

• Hyperthyroidism
• Hypothyroidism

Hypothyroidism leads the market with 79% market share in 2024, due to its growing prevalence, particularly among women, older adults, and individuals with autoimmune conditions like Hashimoto’s thyroiditis. The chronic nature of the disease necessitates lifelong hormone replacement therapy, ensuring a consistent patient base. Rising awareness about hormonal imbalances, improved diagnostic screening, and government health initiatives promoting early detection have significantly increased the number of diagnosed cases. Dietary changes, sedentary lifestyles, and environmental factors have also contributed to disease incidence, creating a positive thyroid gland disorder treatment market outlook. Pharmaceutical companies continue to focus on developing precise levothyroxine formulations and patient-friendly delivery methods. The sustained demand for effective long-term management solutions solidifies hypothyroidism’s dominant position within the global thyroid disorder treatment market.

Analysis by Route of Administration:

• Oral
• Intravenous Route

The oral route leads the market with 85% market share in 2024, because of its simplicity, safety, and patient convenience. Oral tablets enable accurate dosing and are easy to incorporate into daily routines, promoting adherence to long-term therapies like levothyroxine. High bioavailability and predictable absorption through the gastrointestinal tract enhance therapeutic outcomes, making oral administration suitable for chronic management. The availability of multiple strengths and generic options further supports affordability and accessibility across all demographics. Healthcare professionals also favor this route for its non-invasive nature, reduced infection risk, and ease of prescription. According to the thyroid gland disorder treatment market forecast, ongoing advancements in tablet formulation and sustained-release technologies reinforce the continued dominance of oral administration in the market.

Analysis by Distribution Channel:

• Wholesaler/Distributor
• Retailer
• Online
• Others

Wholesaler and distributor leads the market with 63.5% market share in 2024, due to their vital role in ensuring consistent drug availability across hospitals, clinics, and pharmacies. They maintain extensive supply chain networks that facilitate the timely distribution of essential thyroid medications, including levothyroxine, to both urban and rural regions. Their partnerships with manufacturers help stabilize pricing and ensure compliance with regulatory standards. Bulk procurement and efficient logistics lower operational costs, allowing competitive pricing for end users. As thyroid disorders require continuous therapy, the reliability of wholesalers and distributors is crucial in preventing shortages. Their ability to manage inventory, expand reach, and maintain cold-chain integrity further strengthens their leadership in the global distribution landscape.

Regional Analysis:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

In 2024, North America accounted for the largest market share of over 40.7%. The North America thyroid disorder treatment market demand is driven by a high prevalence of thyroid-related conditions, including hypothyroidism and hyperthyroidism, supported by advanced healthcare infrastructure and widespread access to diagnostic services. Rising awareness about early detection and treatment, along with regular screening programs, ensures timely diagnosis and boosts demand for therapies. Increased adoption of combination drug treatments and user-friendly medications, such as daily oral tablets, enhances patient compliance. Lifestyle factors like iodine deficiency, smoking, and excessive alcohol consumption further elevate risk levels, creating sustained treatment needs. Additionally, strong government initiatives, robust insurance coverage, and significant investments in research and development for innovative drug formulations contribute to the market’s steady growth across the United States and Canada.

Key Regional Takeaways:
 

United States Thyroid Gland Disorder Treatment Market Analysis

In 2024, the United States accounted for 72% of the thyroid gland disorder treatment market in North America. The United States is experiencing growing thyroid gland disorder treatment adoption due to growing consumption of alcohol and tobacco, which has been increasingly associated with higher risks of thyroid dysfunction. For instance, over 14 million adults in the United States struggle with alcohol use disorder, while excessive consumption is associated with nearly 95,000 deaths annually. Rising awareness among patients regarding the complications linked to thyroid hormone imbalance and the availability of advanced diagnostic tests are also influencing treatment uptake. Improved access to healthcare specialists and expanding pharmaceutical options for thyroid therapy support the treatment landscape. Lifestyle changes, including stress and dietary habits, further contribute to the growing incidence of thyroid problems, which in turn fosters demand for thyroid gland disorder treatment across the United States healthcare system.

Asia Pacific Thyroid Gland Disorder Treatment Market Analysis

Asia-Pacific is witnessing growing thyroid gland disorder treatment adoption due to growing iodine deficiency, which remains a significant health challenge in several parts of the region. For instance, it is estimated that more than 200 million people are at risk of IDD in India. Increasing public health campaigns and screening programs are enhancing awareness about thyroid health, while technological advancements in endocrinology diagnostics are improving detection rates. Rising healthcare infrastructure development and wider access to treatment options contribute to early intervention. Nutritional imbalances linked to diet also intensify thyroid issues, further accelerating the adoption of treatments. Strong efforts by healthcare providers to expand specialized endocrine care are driving patient engagement, leading to higher demand for thyroid gland disorder treatment.

Europe Thyroid Gland Disorder Treatment Market Analysis

Europe shows expanding thyroid gland disorder treatment adoption due to growing old age population, as elderly individuals are more prone to both hypothyroidism and hyperthyroidism. With age-related changes in thyroid function, older populations increasingly require consistent monitoring and treatment solutions. According to the WHO, the number of people aged 60 and above is rising quickly across the WHO European Region. In 2021, the population stood at 215 million, and is expected to reach 247 million by 2030, and surpass 300 million by 2050. The rise in geriatric demographics across the region has intensified the demand for hormone replacement therapies, advanced diagnostics, and personalized healthcare services. Awareness among patients and caregivers about managing thyroid disorders is contributing to higher treatment uptake. Moreover, healthcare systems across the region emphasize chronic disease management, ensuring that thyroid disorders among the old age population remain a critical treatment focus.

Latin America Thyroid Gland Disorder Treatment Market Analysis

Latin America is experiencing increased adoption of thyroid gland disorder treatments, driven by the rising popularity of online pharmacies. The growing digital platforms provide patients with easier access to medications, convenient home delivery, and a wider range of treatment options. This trend is enhancing treatment adherence, expanding patient reach, and supporting timely management of thyroid-related health conditions across the region.

Middle East and Africa Thyroid Gland Disorder Treatment Market Analysis

Middle East and Africa is showing growing thyroid gland disorder treatment adoption due to growing healthcare facilities, which are enhancing the accessibility of specialized endocrinology services. For instance, in 2025, the UAE is currently home to over 150 hospitals and has more than 5,000 healthcare facilities. Expansion of hospitals and clinics, along with improved diagnostic capabilities, enables earlier detection of thyroid issues. Rising public health awareness is encouraging people to seek timely treatment, and the establishment of specialized thyroid care services is further driving thyroid gland disorder treatment adoption across the Middle East and Africa.

Competitive Landscape:

The thyroid disorder treatment market is highly competitive, with global and regional players focusing on innovation, strategic alliances, and product diversification. Leading pharmaceutical companies emphasize research and development to introduce advanced drug formulations and combination therapies for improved efficacy and patient compliance. Key strategies include mergers, acquisitions, and partnerships to expand market reach and enhance distribution networks. Major players also invest in patient awareness campaigns and digital healthcare solutions to strengthen brand presence. In North America, robust regulatory support and strong healthcare infrastructure enable rapid adoption of new treatments. Continuous clinical trials, patent extensions, and expansion into emerging markets further intensify competition, ensuring a dynamic environment for sustained growth and technological advancements in thyroid disorder management.

The report provides a comprehensive analysis of the competitive landscape in the global thyroid gland disorder treatment market with detailed profiles of all major companies, including:

• Abbott Laboratories
• Abbvie Inc.
• Alvogen
• GSK plc
• IBSA Pharma Inc. (IBSA Group)
• Lannett Company Inc.
• Merck KGaA
• Pfizer Inc.
• RLC Labs Inc.
• Viatris Inc.

Latest News and Developments:

• August 2025: UNC Lineberger launched a first-of-its-kind clinical trial for thyroid gland disorder treatment, testing a combination of zanzalinitinib and cemiplimab in BRAF wildtype anaplastic thyroid cancer patients to improve surgical outcomes and survival rates for those lacking effective options.
• May 2025: Viridian Therapeutics announced that the US FDA granted Breakthrough Therapy Designation to veligrotug for treating thyroid eye disease, following its success in meeting all primary and secondary endpoints in the pivotal THRIVE and THRIVE-2 trials. The therapy showed swift and clinically significant improvements in both diplopia and proptosis across active and chronic cases, marking an important advancement for patients.
• May 2025: The Medicines and Healthcare products Regulatory Agency (MHRA) authorized teprotumumab as the first approved therapy in the UK for adults with moderate to severe Thyroid Eye Disease, representing a major breakthrough in managing this autoimmune disorder while maintaining careful safety monitoring.
• March 2025: Sernova Biotherapeutics revealed that the US FDA has approved its Investigational New Drug application to test the Cell Pouch bio-hybrid organ combined with autograft thyroid cells in hypothyroidism patients, representing a major milestone in thyroid-focused regenerative treatments.
• January 2025: Sling Therapeutics reported encouraging topline findings from its Phase 2b/3 LIDS clinical study, showing that the oral small molecule linsitinib significantly reduced proptosis in thyroid eye disease patients and was well-tolerated, with a confirmatory Phase 3 trial planned for 2025.

Thyroid Gland Disorder Treatment Market Report Scope:

Key Benefits for Stakeholders: 

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the thyroid gland disorder treatment market from 2019-2033.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global thyroid gland disorder treatment market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's Five Forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the thyroid gland disorder treatment industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.